Lakewood-Amedex Biotherapeutics Inc. LABT
- Market cap
- $4.3M
- P/E
- 0.0×
Follow LABT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
Low Price | ||
| — | — | — | — | — | — | — | — | — | — | High Price | |||
| — | — | — | — | — | — | — | — | — | 5 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (5) | (4) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (5) | (4) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (7.03) | (5.53) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (8.28) | (2.79) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (8.29) | (2.79) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.59 | (2.82) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (6) | (2) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | — |
Capex
|
|||
| — | — | — | — | — | — | — | — | (6) | (2) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 0 | (2) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (1) | 0 |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 0 | (2) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (753.49%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 749.24% |
ROE
|
|||
Lakewood-Amedex Biotherapeutics Inc. (LABT) Latest News
24 Sep
Lakewood-Amedex said it dosed the first patient in its Phase 2a study of Nu-3, a topically applied antimicrobial gel for mildly infected diabetic foot ulcers. The milestone accelerates Nu-3 development and tests safety and efficacy across three concentrations—2%, 5% and 10%—in adults with Type 1 or Type 2 diabetes. The trial measures microbial burden reduction and infection resolution to guide dose selection for later studies. After Phase 2a, a Phase 2b will compare the different gel concentrations given once- or twice-daily versus placebo. Topline results are expected in Q1 2027. Nu-3 is designed to rapidly eliminate pathogens at the infection site and address antimicrobial resistance. Shares fell about 3.9% on the news, trading near a 52-week low. Successful Phase 2a dosing milestone could influence dose selection, progression to Phase 2b, and investor sentiment, signaling a meaningful near-term impact on development and valuation.
Lakewood-Amedex Biotherapeutics announces the first patient dosed in its Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers (iDFU). Nu-3 is a topical antimicrobial gel designed to rapidly reduce local microbial burden and address antimicrobial resistance. The multicenter, single-blinded dose-finding study tests three concentrations (2%, 5%, 10%) to evaluate safety and efficacy and inform dose selection, with the program advancing to a Phase 2b comparing once- or twice-daily applications to placebo. The topline results are expected in Q1 2027. The company says Nu-3 sits within its Bisphosphocin® antimicrobial platform, and PERI is managing the trial. Company executives emphasize Nu-3 as a potential new treatment to control infection, support healing, and preserve the limb, addressing the significant clinical challenge of infected diabetic foot ulcers. Phase 2a initiation with multiple concentrations and expected Q1 2027 topline data offers a meaningful near-term milestone but outcomes remain uncertain.
21 Sep
Lakewood-Amedex Biotherapeutics announced its Nasdaq Capital Market listing under LABT, a $7.5 million private placement, and continued progress of Nu-3, a topical Bisphosphocin® gel for infected diabetic foot ulcers. Preclinical data showed safety, tolerability, and low systemic exposure, supporting 2%, 5%, and 10% dose selection for a forthcoming Phase 2a trial. David G. Armstrong, DPM, MD, Ph.D., was named Study Chair and Scientific Advisor for the Phase 2a program, with PERI leading the trial. The company expanded its global IP portfolio to 72 granted patents and 29 pending. Lakewood-Amedex also highlighted Nu-3's rapid, broad-spectrum activity against multidrug-resistant pathogens without inducing resistance. The letter notes improved liquidity, balance sheet strengthening, and plans to pursue a broader Bisphosphocin® platform while seeking shareholder approvals for authorized shares and potential reverse split. Nasdaq listing, $7.5M private placement, and Phase 2a advancement create substantial near-term value and de-risk the pipeline.
18 Sep
Lakewood-Amedex Biotherapeutics gains IRB approval and site readiness to begin Phase 2a clinical trial of Nu-3 for infected diabetic foot ulcers. Initiating Phase 2a trial marks major pipeline advancement and regulatory milestone for the company.
26 Aug
Lakewood-Amedex Biotherapeutics Inc. advances toward Phase 2a study of Nu-3 for infected diabetic foot ulcers. Phase 2a advancement for Nu-3 marks a critical clinical milestone that can drive valuation and investor sentiment.
22 Jul
Lakewood-Amedex Biotherapeutics highlights Nu-3 resistance data in response to the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria national action plan. Nu-3 resistance data alignment with national antibiotic plan may enhance company visibility in antimicrobial development.
15 Jul
Lakewood-Amedex Biotherapeutics announced preclinical safety data supporting clinical dose selection for its upcoming Phase 2a trial of Nu-3 Gel. Preclinical safety data advances Nu-3 Gel development toward Phase 2a trials with moderate effect on pipeline progress.
13 Jul
Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics Inc., discussed company operations, biotherapeutic developments and strategic outlook in an interview. CEO discussion offers moderate strategic insights likely to influence market sentiment without major immediate changes.
25 Jun
Lakewood-Amedex Biotherapeutics appoints David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a trial of Nu-3 in infected diabetic foot ulcers. Expert appointment advances Phase 2a trial for Nu-3 in diabetic foot ulcers.
23 Jun
Lakewood-Amedex Biotherapeutics Inc. develops a next-generation antimicrobial platform as coverage is initiated. Coverage initiation signals analyst attention toward the company's antimicrobial platform efforts.
22 Jun
Lakewood-Amedex Biotherapeutics Inc. secured a composition of matter patent protecting new Bisphosphocin compounds being developed for high-need antimicrobial infections. Patent protection for new pipeline compounds strengthens Lakewood-Amedex's intellectual property position and development prospects in antimicrobials.
27 May
Lakewood-Amedex Biotherapeutics expands global IP portfolio for lead candidate Nu-3 targeting infected diabetic foot ulcers. IP expansion for Nu-3 adds patent protection to the core product but represents routine biotech development without major strategic shift.
18 May
Lakewood-Amedex Biotherapeutics reports positive data advancing lead candidate Nu-3 for infected diabetic foot ulcers. Positive data on lead candidate Nu-3 signals major pipeline progress for diabetic foot ulcer treatment.
12 May
Lakewood-Amedex Biotherapeutics Inc. (LABT) has announced an agreement with PERI to serve as the contract research organization for the Phase 2 clinical trial of Nu-3. Partnership enables Phase 2 testing of Nu-3, supporting pipeline advancement without immediate major financial or market shifts.
23 Apr
Lakewood-Amedex Biotherapeutics Inc. has announced a direct listing on Nasdaq with shares now trading under the symbol LABT. Direct Nasdaq listing provides LABT with increased liquidity and broader investor exposure.